Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas.

Twenty-five evaluable patients with gliomas were treated with a combination of cytosine arabinoside plus cisplatin administered intravenously (IV). Ten of the 25 patients (40%) responded, including three of 13 patients (23%) with prior cranial radiation, and seven of 12 patients (58%) without prior cranial radiation. In a second study, intramuscular (IM) and oral caffeine were added to IV cytosine arabinoside plus cisplatin. Caffeine-induced seizures prevented escalation of the dose of caffeine to a level that would have been anticipated to potentiate the cytotoxicity of the cytosine arabinoside plus cisplatin. Twelve of 25 treated patients (48%) responded. Most of the patients had not received prior cranial radiation. In a third study, IV cytosine arabinoside was administered in combination with intracarotid and IV cisplatin, plus BCNU and tenoposide (VM-26). This study is continuing to accrue patients. Myelosuppression has been pronounced, but has generally been rapidly reversible. It is too early to comment on efficacy of this combination. Our results to date permit us to conclude that the combination of cytosine arabinoside plus cisplatin is capable of inducing regression of gliomas in some patients. We feel that further studies are warranted.

[1]  J. Maroun,et al.  Intracarotid Chemotherapy with a Combination of 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-Diaminedichloroplatinum (Cisplatin), and 4'-O-Demethyl-1-O-(4,6-O-2-thenylidene-β-D-glucopyranosyl)epipodophyllotoxin (VM-26) in the Treatment of Primary and Metastatic Brain Tumors , 1984 .

[2]  U. Bogdahn.  Chemosensitivity of malignant human brain tumors , 1983, Journal of neuro-oncology.

[3]  S. Woo,et al.  Cisplatin therapy in recurrent childhood brain tumors. , 1982, Cancer treatment reports.

[4]  S. Handel,et al.  A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors. , 1982, Cancer research.

[5]  S. Hilliard,et al.  Response of L1210 leukemia to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea plus 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside). , 1981, Cancer research.

[6]  J. Murnane,et al.  Mice, men, mustard and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents. , 1981, British Journal of Cancer.

[7]  V. Levin,et al.  Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. , 1978, Journal of neurosurgery.

[8]  K. Shimazu,et al.  Abnormal Hemispheric Blood Flow and Metabolism in Cerebrovascular Disease. II. Therapeutic Trials With 5% CO2 Inhalation, Hyperventilation and Intravenous Infusion of THAM and Mannitol , 1972, Stroke.

[9]  J. Maroun,et al.  Cisplatin, arabinofuranosyl cytosine, and caffeine before radiation for glioblastomas , 1986 .

[10]  D. Stewart.  Novel modes of chemotherapy administration. , 1984, Progress in experimental tumor research.

[11]  B. Barlogie,et al.  Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine. , 1981, Cancer research.

[12]  F. Schabel,et al.  Chapter 2 – COMBINATION CHEMOTHERAPY WITH NITROSOUREAS PLUS OTHER ANTICANCER DRUGS AGAINST ANIMAL TUMORS1 , 1981 .

[13]  K. Shimazu,et al.  Effect of regional cerebral blood flow of compression by a mass lesion. , 1972, European neurology.